Luvometinib

DRUG6 trials

Conditions

EpendymomaLangerhans Cell HistiocytosisLangerhans Cell Histiocytosis (LCH)Low-grade GliomaMeningiomaNF2NF2-related SchwannomatosisNeurofibromatosis Type 2

Phase 1

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

Not yet recruitingNCT07708285

Beijing Tiantan HospitalMeningioma, Neurofibromatosis Type 2, NF2 +2

Start: 2026-07-31End: 2029-12-31Target: 30Updated: 2026-07-16

Phase 2

Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

Not yet recruitingNCT07713745

Beijing Tiantan HospitalEpendymoma, Meningioma, Neurofibromatosis Type 2 +4

Start: 2026-07-18End: 2036-12-31Target: 200Updated: 2026-07-20

Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis

Not yet recruitingNCT07728201

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityLangerhans Cell Histiocytosis

Start: 2026-06-30End: 2030-06-30Target: 30Updated: 2026-07-27

Phase 3

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

Not yet recruitingNCT07004075

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration

Start: 2025-06-30End: 2029-04-30Target: 102Updated: 2025-06-04

Unknown Phase

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

RecruitingNCT07371182

West China Second University HospitalLangerhans Cell Histiocytosis (LCH)

Start: 2026-06-19End: 2030-12-31Target: 62Updated: 2026-01-27

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

RecruitingNCT07431060

West China Second University HospitalLangerhans Cell Histiocytosis (LCH)

Start: 2026-02-13End: 2030-12-31Target: 120Updated: 2026-02-24

Luvometinib

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase